FI950774A0 - Preparation for transdermal application containing 3-ketodesogestrel - Google Patents

Preparation for transdermal application containing 3-ketodesogestrel

Info

Publication number
FI950774A0
FI950774A0 FI950774A FI950774A FI950774A0 FI 950774 A0 FI950774 A0 FI 950774A0 FI 950774 A FI950774 A FI 950774A FI 950774 A FI950774 A FI 950774A FI 950774 A0 FI950774 A0 FI 950774A0
Authority
FI
Finland
Prior art keywords
ketodesogestrel
preparation
transdermal application
application containing
transdermal
Prior art date
Application number
FI950774A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI950774A (en
Inventor
Ralph Lipp
Clemens Guenther
Jutta Riedl
Ulrich Taeuber
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of FI950774A0 publication Critical patent/FI950774A0/en
Publication of FI950774A publication Critical patent/FI950774A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A transdermal application agent is characterized in that it contains 3-keto-desogestrel, if required combined with one or two estrogens.
FI950774A 1992-08-21 1995-02-20 A preparation for use in a transdermal application containing 3-ketodesogestrel FI950774A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4227989A DE4227989A1 (en) 1992-08-21 1992-08-21 Agent for transdermal application containing 3-keto-desogestrel
PCT/EP1993/002224 WO1994004157A1 (en) 1992-08-21 1993-08-19 Transdermal application agent containing 3-keto-desogestrel

Publications (2)

Publication Number Publication Date
FI950774A0 true FI950774A0 (en) 1995-02-20
FI950774A FI950774A (en) 1995-02-20

Family

ID=6466236

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950774A FI950774A (en) 1992-08-21 1995-02-20 A preparation for use in a transdermal application containing 3-ketodesogestrel

Country Status (13)

Country Link
EP (1) EP0655916B1 (en)
JP (1) JPH08500584A (en)
AT (1) ATE162945T1 (en)
AU (1) AU687013B2 (en)
CA (1) CA2141690A1 (en)
DE (2) DE4227989A1 (en)
DK (1) DK0655916T3 (en)
ES (1) ES2115071T3 (en)
FI (1) FI950774A (en)
GR (1) GR3026627T3 (en)
HU (1) HUT69406A (en)
NO (1) NO307325B1 (en)
WO (1) WO1994004157A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408457A (en) * 1993-12-27 1997-08-05 Akzo Nobel Nv Percutaneous pharmaceutical preparation
AU5971294A (en) * 1994-01-27 1995-08-15 Schering Aktiengesellschaft Agent, intended for transdermal administration, containing 14alpha,17alpha-ethanoestra-1,3,5(10)-triene-3,17beta -diol
DE4405899A1 (en) * 1994-02-18 1995-08-24 Schering Ag Agent for transdermal application containing desogestrel
UA48973C2 (en) * 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Transdermal patch containing 17-deacetyl norgestimate for preventing ovulation
AU6614096A (en) * 1995-07-17 1997-02-18 Schering Aktiengesellschaft Agent, for transdermal application, containing esters of 3-ketodesogestrel
KR100496109B1 (en) * 1996-06-11 2005-09-09 아벤티스 파마 소시에떼아노님 Transdermal Systems Containing Two Active principles in Separate Compartments, Their Method of Preparation and Application as Medicine
FR2749514B1 (en) * 1996-06-11 1998-08-07 Hoechst Marion Roussel TRANSDERMAL SYSTEMS CONTAINING 2 ACTIVE INGREDIENTS IN SEPARATE COMPARTMENTS, THEIR PREPARATION METHOD AND THEIR APPLICATION AS A MEDICAMENT
DE19629468A1 (en) * 1996-07-11 1998-01-15 Schering Ag Transdermal therapeutic systems
US6987101B1 (en) * 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
ES2154253T3 (en) 1997-12-22 2012-01-27 Bayer Healthcare Llc INHIBITION OF THE ACTIVITY OF P38 CINASA USING REPLACED HETEROCYCLIC UREAS.
WO1999045886A2 (en) * 1998-03-09 1999-09-16 Akzo Nobel N.V. New contraceptive kit for monotherapy
AU5619399A (en) * 1998-08-11 2000-03-06 Akzo Nobel N.V. Progestogen-only contraceptive kit providing good cycle control
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
DK1380301T3 (en) 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Pharmaceutical composition of ethinylestradiol and drospirenone for use as a contraceptive
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2275931T5 (en) 2001-12-03 2018-10-23 Bayer Healthcare Llc Aryl urea compounds in combination with other cytostatic or cytotoxic agents for the treatment of human cancers
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
AU2003296810A1 (en) * 2002-12-10 2004-07-09 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration comprising a progestin or an estrogen, method for preparing same and uses thereof
FR2848112B1 (en) * 2002-12-10 2007-02-16 Besins Int Belgique PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY COMPRISING AT LEAST ONE PROGESTATIVE AND / OR AT LEAST ONE OESTROGEN, PREPARATION METHOD AND USES THEREOF
FR2851470B1 (en) 2003-02-20 2007-11-16 Besins Int Belgique PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY
US20090181075A1 (en) * 2005-07-15 2009-07-16 Gordon Ryan D Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
PL2450041T3 (en) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Improved testosterone gel for use in the treatment of hypogonadism
JP2009513707A (en) 2005-10-31 2009-04-02 バイエル ヘルスケア リミティド ライアビリティ カンパニー Diaryl urea and concomitant drugs
MX2008014953A (en) 2006-05-26 2009-03-05 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer.
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
TW200840595A (en) * 2006-12-12 2008-10-16 Organon Nv Oral contraceptive spray
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
BRPI0814697B8 (en) * 2007-07-10 2021-05-25 Agile Therapeutics Inc drug delivery device
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3333240A1 (en) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
CN1021196C (en) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) Prepn. method of progestin unit and system
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
IE71202B1 (en) * 1990-12-17 1997-02-12 Akzo Nv Progestagen-only contraceptive

Also Published As

Publication number Publication date
HUT69406A (en) 1995-09-28
ES2115071T3 (en) 1998-06-16
EP0655916A1 (en) 1995-06-07
NO307325B1 (en) 2000-03-20
AU687013B2 (en) 1998-02-19
AU4950493A (en) 1994-03-15
GR3026627T3 (en) 1998-07-31
ATE162945T1 (en) 1998-02-15
WO1994004157A1 (en) 1994-03-03
HU9500510D0 (en) 1995-04-28
DE59308124D1 (en) 1998-03-12
JPH08500584A (en) 1996-01-23
FI950774A (en) 1995-02-20
DK0655916T3 (en) 1998-09-23
DE4227989A1 (en) 1994-06-09
NO950626D0 (en) 1995-02-20
EP0655916B1 (en) 1998-02-04
CA2141690A1 (en) 1994-03-03
NO950626L (en) 1995-02-20

Similar Documents

Publication Publication Date Title
FI950774A0 (en) Preparation for transdermal application containing 3-ketodesogestrel
AU2059695A (en) Gestodene-containing agent for transdermal administration
NO931209D0 (en) DEVICE FOR TARNSDERMAL SUPPLY OF CONTRASE OPTIVES
DE69311556D1 (en) INHALATION POWDER CONTAINING ANTISTATIC AUXILIARY AGENT
DE68912237D1 (en) Vapor-sensitive composition and sterilization-indicating composition containing it.
HUP9903515A3 (en) 21-substituted progesterone derivatives as new antiprogestational agents medicoments containing the same, use thereof
IL104915A0 (en) Pharmaceutical composition containing estrogen,progestin and antiprogestin and kits containing the same
FI893127A0 (en) FILM COMPOSITION IN THE FILM.
WO1989001342A3 (en) Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
GR1000118B (en) Composition 1,2-dioetans and intermediate substances for it
DE69112372D1 (en) Planetary mixer.
EP0683668A4 (en) Compositions and methods for transdermal drug delivery.
NO963433L (en) Agent for transdermal application containing desogestrel
NO891824D0 (en) The adhesive composition.
EP0274524A4 (en) Pyridone-pyridyl-imidazolyl and triazolyl compounds and their use as cardiotonic agents.
DE68907609D1 (en) MEDICINAL COMPOSITION.
NL1002937A1 (en) Ready-to-use infusion set.
AU515045B2 (en) Injectable male sterilant for selectively controlling the function ofthe testes
DE59712215D1 (en) TRANSDERMALES THERAPEUTIC SYSTEM WITH A BISPHOSPHATE COMBINATION CONTAINING OSTRIOLS
ATE205717T1 (en) ANTIFUNGAL COMPOSITION CONTAINING CROTAMITON AND SALICYL ALDEHYDE
FR2707481B3 (en) Adhesive plaster.
ATE102484T1 (en) HORMONAL COMPOSITION AND USE.
ATE82138T1 (en) REGULATED ADMINISTRATION COMPOSITION.
UA6775A (en) Calefacient composition for skin application
ES1023779Y (en) PERFECTED PLASTER DISPENSER MIXING DEVICE.